# Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

> **NCT02169583** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 24 (actual)

## Conditions studied

- Infections, Respiratory Tract

## Interventions

- **DRUG:** GSK1325756 Solution
- **DRUG:** GSK1325756 Solution Matching Placebo
- **DRUG:** GSK1325756 Tablet
- **DRUG:** GSK1325756 Tablet Matching Placebo

## Key facts

- **NCT ID:** NCT02169583
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-12
- **Primary completion:** 2014-08-28
- **Final completion:** 2014-08-28
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169583

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169583, "Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02169583. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*